Juergen Stickelberger’s Post

Clarivate released the 2024 Companies to Watch report, highlighting seven innovative companies advancing antibody drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. The companies - Adcendo, Araris Biotech AG, GO Therapeutics, Heidelberg Pharma AG, Pheon Therapeutics, Tallac Therapeutics, Tubulis GmbH – are transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest. The report, based on data from BioWorld News and an analysis of drug benefits, financing, and R&D activity, explains why these companies are significant innovators. "Data reveals a clear trend: Big Pharma is swiftly integrating ADCs into their portfolios through partnerships and acquisitions. ADCs are rapidly maturing in the clinical space, expanding beyond oncology into diverse therapeutic areas” quotes Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership at Clarivate. Read more: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma

📣 Adcendo has been featured in Clarivate for Life Sciences & Healthcare's "Companies to Watch: Antibody Drug Conjugates" report! 📰 The report highlights this exciting field of therapeutics and shines a spotlight on companies making an impact in the #lifesciences and #healthcare space. Adcendo is highlighted as one of seven companies that are advancing antibody-drug conjugates (#ADCs) to deliver highly targeted cancer treatments with an improved therapeutic window. Find out more about what makes us stand out, our R&D activities to date, and much more in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences

Latest Life Science News / Updates : 📌 Regeneron is committing up to $500 million over the next five years for its new private financing arm. 📌 Clario has purchased ArtiQ, an artificial intelligence software developer that creates AI solutions for diagnosing and treating patients with respiratory disease. 📌 Genmab announces acquisition of ProfoundBio for $1.8 billion 📌 Obsidian Therapeutics has raised $160 million in a series C. 📌 Alterome Therapeutics, Inc Therapeutics has closed a $132 million series B, cash that will go toward the development of next-gen, small molecule targeted oncology therapies. 📌 Diagonal Therapeutics has raised $128 million to advance its antibody agonist-building platform. 📌 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. 📌 Lonza have appointed new CEO - Wolfgang Wienand

Third Arc Bio originally sought $100 million for its Series A, but with a star-studded executive team that has brought more than 15 new medicines to market, the biotech ended up reeling in $165 million. Founded by Johnson & Johnson veteran Sanjaya Singh and led by former J&J global oncology leader Peter Lebowitz, the Philadelphia-area startup will test its multispecific antibodies in solid tumors and I&I conditions starting next year. Its Series A includes many crossover and public investors, giving the nascent company multiple options before its capital runs dry in roughly three years. “At J&J, I saw all the platforms. We had them all. I specifically wanted to work on [multispecific antibodies] because this is the area where there is the largest opportunity to meet unmet need,” Lebowitz said in an interview with Endpoints News. “There’s a lot of interest in ADCs now, and ADCs are very important. But this is the area that is right in the right spot of the breaking point where it goes over the edge and actually is transformational for solid tumors.” #biotech #venturecapital #biotechvc #thirdarc #biologics #multispecificantibodies #solidtumors #autoimmune #immunology #drugdevelopment

Boldly going ...to tackle the 'high-hanging fruit in oncology." More oncology pipeline developments from Merck; this as it relates to the potential of macrocyclic peptides coupled with AI platforms through a collaboration partnership with California-based Unnatural Products Inc. (UNP). "UNP is working on a new approach centered on macrocycles and cyclic peptides, designed through its AI-driven platform, to address traditionally hard-to-reach intracellular targets. The compounds may help expand the druggable genome by hitting targets that are otherwise too complex for small molecules, or replicating the potency and selectivity of antibodies, but in an oral dosage form." https://lnkd.in/eKEpcP7M #Merck #MerckResearchLabs #Oncology #UnnaturalProducts #Biotech #Innovation #TargetedTherapies #IntracellularTargeting #Pharma #Healthcare

🔬Debiopharm, an independent biopharmaceutical leader, is collaborating with ThinkingNode Life Science, Inc., a trailblazer in AI-powered drug discovery, to revolutionize cancer drug development with AI. 💡This partnership promises to enhance healthcare by: - Expanding drug indications by identifying new applications to benefit more patients. - Optimizing combination therapies for greater efficacy. - Validating mechanisms of action for targeted treatments. Conducting comparative analyses for optimal drug selection and development. 🎯The impact? Improved patient outcomes, a global advancement in cancer treatment, and a leap forward in healthcare innovation. Bertrand Ducrey, CEO of Debiopharm, calls it a "significant leap forward in cancer drug development." 🔄 What possibilities do you see in the integration of AI in cancer care and healthcare as a whole? Share your thoughts below ⬇️ #cancercare #cancertreatment #healthcareinnovation #healthcaremanagement #oncology Source: https://lnkd.in/g5pK9Fiy Disclaimer: Synthesised content in posts is purely my own and based on outside-in analysis of public data sources; it does not endorse nor reflect views of any current or past institutional affiliations

In a recent podcast, Allucent experts Sugato De, MS (VP, Regulatory Strategy, Head of MedTech) and Alex MacDonald, PhD (VP, Model Informed Drug Development) explored the exciting world of antibody drug conjugates (ADCs) and radionuclide drug conjugates (RDCs), discussing the tremendous growth potential of these targeted oncology therapies, the challenges faced by small and mid-sized biotech companies, and strategies for navigating the complex regulatory landscape. This podcast was hosted by BioPharma Dive and can be accessed here: https://lnkd.in/g8uSZp7X.   #Allucent #BringNewTherapiesToLife #DrugDiscovery #AntibodyDrugConjugates #Radionuclides #Oncology

Antibody drug conjugates (ADCs) are revolutionizing oncology treatment, offering precise drug delivery with minimal side effects and toxicity. This technology holds immense promise not only for cancer therapies but also for potential applications in other medical fields. In the latest "2024 Companies to Watch" report, we spotlight seven trailblazing firms at the forefront of ADC innovation. These companies are pioneering the development of highly targeted cancer treatments that promise to reshape patient care and outcomes. Stay tuned as we dive into how these innovative ADC makers are partnering with pharmaceutical giants and advancing breakthrough therapies that could redefine the future of medicine. 🚀💊 Free download below: https://lnkd.in/g-z-B5J4

🌟 Exploring the Future of Cancer Biologics: Insights for 2024-2028 🌟 Exciting advancements are on the horizon in the field of cancer treatment! The latest article from Medium provides an in-depth look at the trends, innovations, and growth prospects in the cancer biologics market over the next few years. 🔬 Key Highlights: - Emerging Trends: Discover the latest trends shaping the future of cancer biologics. - Innovative Approaches: Explore groundbreaking innovations that are transforming treatment strategies. - Market Growth: Gain insights into the projected growth and key factors driving this dynamic market. For anyone interested in the future of oncology and the advancements in biologics, this article is a must-read. Dive into the details and stay ahead of the curve in understanding how these developments could impact the industry and patient outcomes. 👉 Read the full article at https://lnkd.in/g7q4FSMb #CancerBiologics #Oncology #HealthcareInnovation #MarketTrends #Biologics #MedicalResearch

#News: Apparently, C4 Therapeutics, Inc. ' #proteindegradation tech brings all the #Mercks to the yard. The Massachusetts #biotech has signed on MSD in a $740 million biobucks partnership to find two #degraders for #cancer. #MerckKGaA is offering $16 million upfront and $740 million in #biobucks for the two degraders aimed at proteins that drive cancer growth. Merck will pay for C4’s discovery work and be responsible for future clinical development, according to Monday's announcement. C4 also stands to make mid single- to low double-digit royalties should any of the targets turn into marketed drugs. Paul Lyne , head of Merck KGaA’s oncology research unit, said the deal adds more depth to the company’s protein degradation investments. Read more from Fierce Biotech 👇🏽 https://lnkd.in/e-f7TuHZ